Credit Suisse’s Phibro Animal Health PAHC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $774K | Buy |
59,851
+2,588
| +5% | +$31K | ﹤0.01% | 2415 |
|
|
2023
Q4 | $663K | Buy |
57,263
+8,043
| +16% | +$90.8K | ﹤0.01% | 2589 |
|
|
2023
Q3 | $629K | Buy |
49,220
+1,061
| +2% | +$15K | ﹤0.01% | 2563 |
|
|
2023
Q2 | $660K | Buy |
48,159
+24,233
| +101% | +$347K | ﹤0.01% | 2641 |
|
|
2023
Q1 | $367K | Buy |
23,926
+2,728
| +13% | +$41.7K | ﹤0.01% | 2912 |
|
|
2022
Q4 | $284K | Buy |
21,198
+5,374
| +34% | +$72.1K | ﹤0.01% | 3067 |
|
|
2022
Q3 | $211K | Buy |
15,824
+112
| +0.7% | +$1.93K | ﹤0.01% | 3223 |
|
|
2022
Q2 | $300K | Buy |
15,712
+1,236
| +9% | +$23.4K | ﹤0.01% | 3162 |
|
|
2022
Q1 | $289K | Buy |
14,476
+1,080
| +8% | +$21.8K | ﹤0.01% | 3242 |
|
|
2021
Q4 | $274K | Sell |
13,396
-226
| -2% | -$4.83K | ﹤0.01% | 4159 |
|
|
2021
Q3 | $294K | Sell |
13,622
-3,737
| -22% | -$90K | ﹤0.01% | 4094 |
|
|
2021
Q2 | $502K | Buy |
17,359
+2,081
| +14% | +$56.3K | ﹤0.01% | 3835 |
|
|
2021
Q1 | $372K | Sell |
15,278
-8,740
| -36% | -$197K | ﹤0.01% | 3924 |
|
|
2020
Q4 | $466K | Buy |
24,018
+13,124
| +120% | +$241K | ﹤0.01% | 3838 |
|
|
2020
Q3 | $189K | Sell |
10,894
-964
| -8% | -$20.6K | ﹤0.01% | 3842 |
|
|
2020
Q2 | $312K | Buy |
11,858
+414
| +4% | +$10.3K | ﹤0.01% | 3563 |
|
|
2020
Q1 | $277K | Sell |
11,444
-3,185
| -22% | -$77.8K | ﹤0.01% | 3472 |
|
|
2019
Q4 | $363K | Sell |
14,629
-13,106
| -47% | -$304K | ﹤0.01% | 3733 |
|
|
2019
Q3 | $591K | Buy |
27,735
+7,988
| +40% | +$219K | ﹤0.01% | 3347 |
|
|
2019
Q2 | $627K | Buy |
19,747
+3,639
| +23% | +$114K | ﹤0.01% | 3268 |
|
|
2019
Q1 | $532K | Buy |
16,108
+678
| +4% | +$21.1K | ﹤0.01% | 3289 |
|
|
2018
Q4 | $497K | Buy |
15,430
+3,427
| +29% | +$129K | ﹤0.01% | 3260 |
|
|
2018
Q3 | $515K | Sell |
12,003
-4,655
| -28% | -$220K | ﹤0.01% | 3279 |
|
|
2018
Q2 | $767K | Sell |
16,658
-1,654
| -9% | -$73.2K | ﹤0.01% | 3198 |
|
|
2018
Q1 | $728K | Sell |
18,312
-271
| -1% | -$10K | ﹤0.01% | 3165 |
|
|
2017
Q4 | $622K | Sell |
18,583
-3,454
| -16% | -$123K | ﹤0.01% | 3316 |
|
|
2017
Q3 | $817K | Buy |
22,037
+12,894
| +141% | +$484K | ﹤0.01% | 3243 |
|
|
2017
Q2 | $339K | Sell |
9,143
-7,554
| -45% | -$247K | ﹤0.01% | 3393 |
|
|
2017
Q1 | $470K | Sell |
16,697
-21,588
| -56% | -$609K | ﹤0.01% | 3330 |
|
|
2016
Q4 | $1.12M | Buy |
38,285
+2,848
| +8% | +$77.7K | ﹤0.01% | 2940 |
|
|
2016
Q3 | $963K | Sell |
35,437
-44,280
| -56% | -$1M | ﹤0.01% | 2987 |
|
|
2016
Q2 | $1.49M | Buy |
79,717
+57,973
| +267% | +$1.21M | ﹤0.01% | 2581 |
|
|
2016
Q1 | $588K | Sell |
21,744
-16,192
| -43% | -$464K | ﹤0.01% | 3134 |
|
|
2015
Q4 | $1.14M | Sell |
37,936
-21,879
| -37% | -$702K | ﹤0.01% | 2710 |
|
|
2015
Q3 | $1.89M | Buy |
59,815
+18,044
| +43% | +$659K | ﹤0.01% | 2298 |
|
|
2015
Q2 | $1.63M | Sell |
41,771
-23,625
| -36% | -$815K | ﹤0.01% | 2722 |
|
|
2015
Q1 | $2.32M | Buy |
65,396
+38,865
| +146% | +$1.25M | ﹤0.01% | 2266 |
|
|
2014
Q4 | $837K | Buy |
+26,531
| New | +$734K | ﹤0.01% | 3294 |
|
Other funds holding PAHC
BIP
Credit Suisse's PAHC Position: Q1 2024 in Review
Credit Suisse increased its Phibro Animal Health (PAHC) stake by 4.5% in Q1 2024, buying an estimated $31K and bringing the position to 59,851 shares worth $774K. The position accounts for ﹤0.01% of the portfolio, ranked #2415.
Credit Suisse first reported a position in PAHC in Q4 2014 and has held it in 38 quarters since. The position peaked at $2.32M in Q1 2015. 138 funds tracked by Wall St. Rank hold PAHC as of Q1 2024.
- Credit Suisse held 59,851 shares of Phibro Animal Health worth $774K as of Q1 2024.
- Credit Suisse bought 2,588 Phibro Animal Health shares in Q1 2024, an estimated $31K.
- Phibro Animal Health made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2415 holding.
- Credit Suisse first reported a position in Phibro Animal Health in Q4 2014 and has held it in 38 quarters since.
- Credit Suisse's Phibro Animal Health position peaked at $2.32M in Q1 2015.
- 138 funds tracked by Wall St. Rank held Phibro Animal Health as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.